How Low Is Too Low? (Downgrade, Technical Analysis) Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further Novo Nordisk: Full Kitchen Sink Reset Or Another Shoe Yet To Drop? Eli Lilly ...

Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers ...

Eli Lilly will acquire Orna Therapeutics for up to $2.4 billion to gain access to the Watertown biotech's circular RNA ...

Eli Lilly and Company (NYSE:LLY) is included among 13 Best Long Term Low Risk Stocks to Buy Now. On February 5, Goldman Sachs ...

Eli Lilly and Company (NYSE:LLY) executives highlighted strong 2025 performance, continued demand for its incretin medicines, ...

The investment supports Eli Lilly and Company’s $3.5 billion expansion into Upper Macungie Township, marking the largest ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

We decided to exit the Oracle position and book a short-term tax loss, spreading the capital across several of the ...

It’s become clear that Big Pharma is not a friend of ordinary Americans. Prices are too high and have been rising for too ...

Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?

Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.

Novo Nordisk just did Eli Lilly stock a huge favor.